IVITX
Price
$23.05
Change
-$0.41 (-1.75%)
Updated
Feb 21 closing price
Net Assets
157.69M
RMFCX
Price
$57.23
Change
-$0.62 (-1.07%)
Updated
Feb 21 closing price
Net Assets
105.48B
Ad is loading...

IVITX vs RMFCX

Header iconIVITX vs RMFCX Comparison
Open Charts IVITX vs RMFCXBanner chart's image
VY® Invesco Growth and Income S2
Price$23.05
Change-$0.41 (-1.75%)
VolumeN/A
Net Assets157.69M
American Funds American Mutual R3
Price$57.23
Change-$0.62 (-1.07%)
VolumeN/A
Net Assets105.48B
IVITX vs RMFCX Comparison Chart
Loading...
View a ticker or compare two or three
VS
IVITX vs. RMFCX commentary
Feb 23, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IVITX is a Hold and RMFCX is a Buy.

Ad is loading...
FUNDAMENTALS
Fundamentals
RMFCX has more cash in the bank: 105B vs. IVITX (158M). RMFCX pays higher dividends than IVITX: RMFCX (1.69) vs IVITX (1.43). IVITX was incepted earlier than RMFCX: IVITX (22 years) vs RMFCX (23 years). IVITX has a lower initial minimum investment than RMFCX: IVITX (0) vs RMFCX (250). RMFCX annual gain was more profitable for investors over the last year : 11.03 vs. IVITX (3.21). RMFCX return over 5 years is better than : 41.75 vs. IVITX (9.27).
IVITXRMFCXIVITX / RMFCX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence22 years23 years-
Gain YTD3.8294.83679%
Front LoadN/AN/A-
Min. Initial Investment0250-
Min. Initial Investment IRAN/AN/A-
Net Assets158M105B0%
Annual Yield % from dividends1.431.6985%
Returns for 1 year3.2111.0329%
Returns for 3 years-9.1419.69-46%
Returns for 5 years9.2741.7522%
Returns for 10 years-13.9664.83-22%
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
GTBP2.150.02
+0.94%
GT Biopharma
OSBC18.33-0.42
-2.24%
Old Second Bancorp
CNM50.97-1.45
-2.77%
Core & Main
IBRX3.42-0.22
-6.04%
ImmunityBio
CRDL1.20-0.10
-7.69%
Cardiol Therapeutics